Trial Profile
A study evaluating Efficacy and Safety of biosimilar IFX CT-P13 in a Cohort of Patients with Established Behçet'S Disease who were switched from originator Infliximab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jul 2018
Price :
$35
*
At a glance
- Drugs Infliximab (Primary) ; Infliximab
- Indications Behcet's syndrome
- Focus Adverse reactions; Therapeutic Use
- 15 Jul 2018 New trial record
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism